Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013;2013(Suppl 2):001.
doi: 10.4172/2161-1041.S2-001.

Triple Negative Breast Cancer - An Overview

Kartik Aysola  1 , Akshata Desai  2 , Crystal Welch  1 , Jingyao Xu  1 , Yunlong Qin  1 , Vaishali Reddy  1 , Roland Matthews  1 , Charlotte Owens  1 , Joel Okoli  3 , Derrick J Beech  3 , Chandrika J Piyathilake  4 , Shyam P Reddy  1 , Veena N Rao  1
Affiliations

Triple Negative Breast Cancer - An Overview

Kartik Aysola et al. Hereditary Genet. 2013.

Abstract

Triple Negative Breast Cancer (TNBC) is a heterogeneous disease that based on immunohistochemistry (IHC) is estrogen receptor (ER) negative, progesterone receptor (PR) negative and human epidermal growth factor receptor 2 (HER2) negative. TNBC is typically observed in young AA women and Hispanic women who carry a mutation in the BRCA1 gene. TNBC is characterized by a distinct molecular profile, aggressive nature and lack of targeted therapies. The purpose of this article is to review the current and future novel signalling pathways as therapeutic approaches to TNBC. Recent Identification of a new BRCA1 trafficking pathway holds promise in the future for the development of targeted therapies for TNBC.

Keywords: BCL-2; BRCA1; CISPLATIN; EGFR; Hedgehog; NOTCH; PARP; TNBC; UBC9; WNT/B-CATENIN.

PubMed Disclaimer

References

    1. Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist. 2011;16(Suppl 1):61–70. - PubMed
    1. O’Toole SA, Beith JM, Millar EK, West R, McLean A, et al. Therapeutic targets in triple negative breast cancer. J Clin Pathol. 2013 - PubMed
    1. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750–2767. - PMC - PubMed
    1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–1948. - PubMed
    1. Bertucci F, Finetti P, Cervera N, Esterni B, Hermitte F, et al. How basal are triple-negative breast cancers? Int J Cancer. 2008;123:236–240. - PubMed

LinkOut - more resources